LB Pharmaceuticals Stock (NASDAQ:LBRX)
Previous Close
$37.80
52W Range
$13.40 - $50.16
50D Avg
$43.41
200D Avg
$30.48
Market Cap
$1.07B
Avg Vol (3M)
$324.61K
Beta
0.42
Div Yield
-
LBRX Company Profile
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.